HIV infection in combination with other antiretroviral
drugs
▶BY MOUTH
▶Adult: 250–300 mg twice daily
Prevention of maternal-fetal HIV transmission
▶BY MOUTH, OR BY INTRAVENOUS INFUSION
▶Adult: Seek specialist advice (combination therapy
preferred) (consult local protocol)
HIV infection in combination with other antiretroviral
drugs in patients temporarily unable to take zidovudine
by mouth
▶BY INTRAVENOUS INFUSION
▶Adult: 0.8–1 mg/kg every 4 hours usually for not more
than 2 weeks, dose approximating to 1.2–1.5 mg/kg
every 4 hours by mouth
PDF page 714
Abnormally low haemoglobin
concentration (consult product literature). abnormally low
neutrophil counts (consult product literature)
PDF page 714
Elderly. lactic acidosis. risk of haematological
toxicity particularly with high dose and advanced disease.
vitamin B12 deficiency (increased risk of neutropenia)
CAUTIONS, FURTHER INFORMATION
▶Lactic acidosis Lactic acidosis associated with hepatomegaly
and hepatic steatosis has been reported with zidovudine.
Use with caution in patients with hepatomegaly, hepatitis,
or other risk factors for liver disease and hepatic steatosis
(including obesity and alcohol abuse). Discontinue
treatment if symptoms of hyperlactataemia, lactic
acidosis, progressive hepatomegaly or rapid deterioration
of liver function become apparent.
PDF page 714
The
abbreviation AZT which is sometimes used for zidovudine
has also been used for another drug.
PDF page 714